Obstetrics and Gynecology International factors, side eﬀects, and perceived treatment eﬃcacy,” Women and Health, vol. 42, no. 1, pp. 99–115, 2005. [26] A. D. Bardeguez, J. C. Lindsey, M. Shannon et al., “Adherence to antiretrovirals among US women during and after preg- nancy,” Journal of Acquired Immune Deﬁciency Syndromes, vol. 48, no. 4, pp. 408–417, 2008. [27] T. E. Wilson, J. R. Ickovics, M. I. Fernandez, L. J. Koenig, and E. Walter, “Self-reported zidovudine adherence among pregnant women with human immunodeﬁciency virus infection in four US states,” American Journal of Obstetrics and Gynecology, vol. 184, no. 6, pp. 1235–1240, 2001. [28] S. E. Cohn, T. Umbleja, J. Mrus, A. D. Bardeguez, J. W. Ander- sen, and M. A. Chesney, “Prior illicit drug use and missed pre- natal vitamins predict nonadherence to antiretroviral therapy in pregnancy: adherence analysis A5084,” AIDS Patient Care and STDs, vol. 22, no. 1, pp. 29–40, 2008. [29] D. Ciambrone, H. G. Loewenthal, L. B. Bazerman, C. Zorilla, B. Urbina, and J. A. Mitty, “Adherence among women with HIV infection in Puerto Rico: the potential use of modiﬁed directly observed therapy (MDOT) among pregnant and postpartum women,” Women and Health, vol. 44, no. 4, pp. 61–77, 2006. [30] C. Psaros, P. A. Geller, and E. Aaron, “The importance of identifying and treating depression in HIV infected, pregnant women: a review,” Journal of Psychosomatic Obstetrics and Gynecology, vol. 30, no. 4, pp. 275–281, 2009. [31] M. A. Kingston, C. J. Letham, and O. McQuillan, “Adherence to antiretroviral therapy in pregnancy,” International Journal of STD and AIDS, vol. 18, no. 11, pp. 787–789, 2007. [32] S. D. Fairgrieve, M. Jackson, P. Jonas et al., “Population based, prospective study of the care of women with epilepsy in preg- nancy,” British Medical Journal, vol. 321, no. 7262, pp. 674– 675, 2000. [33] J. Williams, V. Myson, S. Steward et al., “Self-discontinuation of antiepileptic medication in pregnancy: detection by hair analysis,” Epilepsia, vol. 43, no. 8, pp. 824–831, 2002. [34] K. Belanger, M. E. Hellenbrand, T. R. Holford, and M. Bracken, “Eﬀect of pregnancy on maternal asthma symptoms and medication use,” Obstetrics and Gynecology, vol. 115, no. 3, pp. 559–567, 2010. [35] K. Chambers, “Asthma education and outcomes for women of childbearing age,” Case Manager, vol. 14, no. 6, pp. 58–61, 2003. [36] V. E. Murphy, P. G. Gibson, P. I. Talbot, C. G. Kessel, and V. L. Clifton, “Asthma self-management skills and the use of asthma education during pregnancy,” European Respiratory Journal, vol. 26, no. 3, pp. 435–441, 2005. [37] V. E. Murphy, V. L. Clifton, and P. G. Gibson, “Asthma exac- erbations during pregnancy: incidence and association with adverse pregnancy outcomes,” Thorax, vol. 61, no. 2, pp. 169– 176, 2006. [38] R. E. Mountiﬁeld, R. Prosser, P. Bampton, K. Muller, and J. M. Andrews, “Pregnancy and IBD treatment: this challenging interplay from a patients’ perspective,” Journal of Crohn’s and Colitis, vol. 4, no. 2, pp. 176–182, 2010. [39] M. J. Nielsen, M. Nørgaard, P. Holland-Fisher, and L. A. Christensen, “Self-reported antenatal adherence to medical treatment among pregnant women with Crohn’s disease,” Ali- mentary Pharmacology and Therapeutics, vol. 32, no. 1, pp. 49– 58, 2010. [40] M. Julsgaard, M. Nrgaard, C. L. Hvas, D. Buck, and L. A. Christensen, “Self-reported adherence to medical treatment prior to and during pregnancy among women with ulcerative 5 colitis,” Inﬂammatory Bowel Diseases, vol. 17, no. 7, pp. 1573– 1580, 2011. [41] L. J. Fish, B. L. Peterson, R. J. R. J. Namenek Brouwer et al., “Adherence to nicotine replacement therapy among pregnant smokers,” Nicotine and Tobacco Research, vol. 11, no. 5, pp. 514–518, 2009. [42] H. Nordeng, E. Ystrøm, and A. Einarson, “Perception of risk regarding the use of medications and other exposures during pregnancy,” European Journal of Clinical Pharmacology, vol. 66, no. 2, pp. 207–214, 2010. [43] R. L. Hancock, G. Koren, A. Einarson, and W. J. Ungar, “The eﬀectiveness of Teratology Information Services (TIS),” Reproductive Toxicology, vol. 23, no. 2, pp. 125–132, 2007. [44] A. Einarson, P. Selby, and G. Koren, “Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling,” Journal of Psychiatry and Neuroscience, vol. 26, no. 1, pp. 44–48, 2001. [45] J. E. Hart, C. Y. Jeon, L. C. Ivers et al., “Eﬀect of directly ob- served therapy for highly active antiretroviral therapy on viro- logic, immunologic, and adherence outcomes: a meta-analysis and systematic review,” Journal of Acquired Immune Deﬁciency Syndromes, vol. 54, no. 2, pp. 167–179, 2010. [46] C. J. McCabe, S. J. Goldie, and D. N. Fisman, “The cost- effectiveness of directly observed highly-active antiretroviral therapy in the third trimester in HIV-infected pregnant women,” PLoS ONE, vol. 5, no. 4, Article ID e10154, 2010.